Universal Corp Dossier - Source-backed chat

Universal Corp

UVVNYSE

SectorConsumer Staples

IndustryTobacco

Beta (adjusted)0.74

Intrinsic Value $44.79median of 4 methods · middle span $44-$46based on filings through 30 Jun 2026

Market Price $41.79Price as of 30 Sep 2026

Near fair valueIntrinsic value is 7% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1B

Enterprise Value $1.5B

Shares Outstanding 25.1M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

Next ex-dividend9 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Universal Corporation (NYSE: UVV) presents a defensive, dividend-heavy profile with a remarkable 56-year track record of annual dividend increases, currently yielding over 6%. However, near-term growth prospects are constrained by structural declines in global cigarette consumption, a temporary oversupply in certain tobacco styles, and operational integration challenges within its Ingredients segment. While the core tobacco business remains highly cash-generative, the company's FY2026 results were heavily impacted by a $41.1 million non-cash goodwill impairment at its Shank's operation and $52.0 million in tobacco inventory write-downs. A 'Hold' rating is recommended as the company undergoes operational resets in its Ingredients platform and works to optimize its uncommitted tobacco inventory down to its target range of 10% to 20% in FY2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$67.00

Mean target$67.00

High · most bullish analyst$67.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case is triggered by persistent oversupply in dark air-cured tobacco, leading to further inventory write-downs. Additionally, the Ingredients segment faces prolonged integration issues, tariff headwinds, or weak consumer-packaged goods demand, resulting in further goodwill impairments. High working capital requirements for larger tobacco crops strain liquidity, and free cash flow fails to cover the dividend, raising concerns over dividend safety and leading to a multiple contraction.

Base CaseCentral scenario

The base case assumes that global tobacco demand continues its slow, steady decline of approximately 1% to 2% annually, which is partially offset by Universal's pricing power and steady market share. The Ingredients segment is expected to stabilize following leadership realignment at Shank's, with segment revenues growing at a low-to-mid single-digit rate. Uncommitted inventory is successfully managed down to the target 10% to 20% range in FY2027, restoring operating margins toward historical averages of 8%. The dividend remains safe but growth is limited to ~1% annually.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Unrivaled dividend track record with 56 consecutive years of annual dividend increases, offering a highly attractive yield of over 6%.
Dominant global market position as the leading independent business-to-business leaf tobacco merchant with a presence in over 30 countries.
Strategic diversification into the higher-growth plant-based ingredients sector, which provides a long-term runway to offset tobacco volume declines.

Key Investment Risks

High customer concentration, where a small number of multinational tobacco manufacturers account for a significant portion of revenues.
Exposure to agricultural risks, weather patterns, and cyclical oversupply, as evidenced by the $52 million in tobacco inventory write-downs in FY2026.
Execution and integration risks in the Ingredients segment, highlighted by the $41.1 million goodwill impairment charge at Shank's in FY2026.

Thesis Invalidation Triggers

A formal dividend cut or suspension, which would destroy the core income-focused investment thesis.
Additional material goodwill impairments in the Ingredients segment, indicating structural failure of the diversification strategy.
A permanent shift by major customers toward vertical integration, bypassing independent merchants like Universal entirely.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.